Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms May 20, 2021
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer May 20, 2021
7 Investment Tips from Kevin O’Leary, Who Says There’s More Money In Psychedelics Than There Is In Cannabis May 19, 2021
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company… May 19, 2021
